Takeda Pharmaceutical Co. has reached an agreement to buy Shire PLC for $62 billion. Photo: Bloomberg via Getty Images

Slaughter and May, Linklaters, Davis Polk & Wardwell, Ashurst and Fried, Frank, Harris, Shriver & Jacobson are among the global firms advising on Japanese pharmaceutical giant Takeda’s $62 billion takeover of Irish drugmaker Shire.

The successful bid is the fifth offer put forward by Takeda, and follows a $58 billion bid that was rejected by Shire in April. It marks the largest-ever overseas acquisition by a Japanese company and would create the world’s eighth-largest drugmaker with combined sales of $30 billion. The acquisition would allow Takeda to achieve its goal of gaining a bigger presence in lucrative markets such as Europe and the United States.

Linklaters is advising Takeda with a team that includes corporate partner James Inglis, global corporate chair Matthew Middleditch and corporate partners Aisling Zarraga and Sarah Flaherty. Global U.S. practice head Tom Shropshire and Japan corporate partner Hiroya Yamazaki are also advising.

Japanese “big four” firm Nishimura & Asahi and offshore firm Ogier are also advising Takeda.

Slaughter and May is acting for regular client Shire, with London-based corporate partners Martin Hattrell and Christian Boney at the helm.

Davis Polk and offshore firm Mourant Ozannes are also advising the Dublin-based company.

Ashurst is advising Evercore Partners, JPMorgan and Nomura, the joint financial advisers to Takeda, with a team led by corporate partners Robert Ogilvy Watson and Tom Mercer alongside banking partner Tim Rennie.

Fried Frank also is advising Evercore, with a team led by co-head of the firm’s mergers and acquisitions practice Philip Richter and litigation partner Scott Luftglass.